Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | C3AR1 | Q16581 | 3/20 | 0.40 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.40 |
| ▸ | PADI6 | Q6TGC4 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
| ▸ | PADI4 | Q9UM07 | 2/20 | 0.38 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | PADI2 | Q9Y2J8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4986587 | 0.85 | BRD4 (0.52) | C3AR1MAPK8ACHEBCHEALB | |
| SCHEMBL4997732 | 0.83 | C3AR1 (0.45) | C3AR1PADI6F10PRSS1PADI4 | |
| SCHEMBL4989846 | 0.82 | C3AR1 (0.56) | C3AR1 | |
| SCHEMBL14090758 | 0.82 | C3AR1 (0.56) | C3AR1 | |
| SCHEMBL4989795 | 0.82 | C3AR1 (0.56) | C3AR1 | |
| SCHEMBL7925397 | 0.80 | C3AR1 (0.52) | C3AR1PADI6ALBPADI4CA1 | |
| SCHEMBL188590 | 0.80 | C3AR1 (0.52) | C3AR1PADI6ALBPADI4CA1 | |
| SCHEMBL188589 | 0.80 | C3AR1 (0.52) | C3AR1PADI6ALBPADI4CA1 | |
| SCHEMBL4987830 | 0.80 | PRSS1 (0.48) | C3AR1PADI6F10PRSS1ERAP2 | |
| SCHEMBL14090765 | 0.80 | PRSS1 (0.48) | C3AR1PADI6F10PRSS1ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | PRMT5 1542/4885C3AR1 1/4885MAPK8 3294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.